Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Rakel MD, FAAFP
David Rakel MD, FAAFP Editor-in-Chief
Jonathan Temte MD, PhD
Jonathan Temte MD, PhD Advisory Board
Irene Hamrick MD, FAAFP, AGSF, CMD
Irene Hamrick MD, FAAFP, AGSF, CMD Advisory Board
See All Experts
featured
Published in Primary Care and
2 other channels

Expert Opinion / Commentary · June 17, 2015

TECOS Shows Sitagliptin Neutrality vis-à-vis MACE in High-Risk CAD

Silvio Inzucchi MD

 

 Save  Recommend
 Share

Additional Info

  1. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335.
  2. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326.

Disclosure statements are available on the authors' profiles:

Silvio Inzucchi MD

Further Reading

Most Read This Week

Recently Updated